Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old drug, new hope: could papaverine soothe chemo nerve damage?

NCT ID NCT07572461

Symptom relief Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether papaverine, a drug that relaxes blood vessels, can relieve nerve pain and numbness caused by taxane chemotherapy. About 43 adults whose symptoms haven't improved with standard treatments will receive daily infusions of papaverine for up to three weeks. The goal is to see if it reduces sensory symptoms and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
papaverine hydrochloride injection
What this could lead to
If it works, this could offer a new option for people with nerve pain from chemotherapy that hasn't improved with standard treatments.
What could go wrong
This is a small, early-phase study with no control group, so results may not be conclusive. It's also not yet recruiting, so outcomes are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 43 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years. * Histologically or cytologically confirmed malignancy. * Prior treatment with a taxane-containing chemotherapy regimen, including but not limited to paclitaxel, docetaxel, or nab-paclitaxel, with completion of chemotherapy at least 4 weeks before enrollment. * Persistent, clinically significant peripheral neuropathy mainly attributed to taxane-based chemotherapy, with NCI-CTCAE v5.0 sensory neuropathy grade ≥ 2. * Failure of at least one standard treatment for chemotherapy-induced peripheral neuropathy, such as duloxetine ≥ 60 mg/day, pregabalin ≥ 150 mg/day, or gabapentin ≥ 900 mg/day, for at least 4 weeks, defined as lack of symptom improvement or intolerance to treatment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Adequate organ function, including hematologic, hepatic, and renal function within acceptable ranges. * Willingness to participate and ability to provide written informed consent. Exclusion Criteria: * Peripheral neuropathy due to causes other than chemotherapy, such as uncontrolled diabetes mellitus (HbA1c \> 7.0%), severe renal insufficiency, vitamin B12 deficiency, thyroid dysfunction, or history of alcohol abuse. * Known hypersensitivity to papaverine or any of its components. * Contraindications to papaverine, such as complete atrioventricular block. * Current use of other investigational drugs that may affect neurological function. * Pregnant or breastfeeding women. * Severe hepatic or renal dysfunction, defined as ALT or AST \> 3 × upper limit of normal or serum creatinine \> 2 × upper limit of normal. * Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy Paclitaxel-induced peripheral neuropathy Refractory chemotherapy-induced peripheral neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.